10 May 2024

## Tender results

Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2022/23 Invitation to Tender, dated 31 October 2022.

Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceutical under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.

## Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:

- For new listings, by 4 pm on the $12^{\text {th }}$ of May 2024 or the $5^{\text {th }}$ of the month prior to listing, whichever is earlier
- For price changes, by 4 pm on the $12^{\text {th }}$ of the month prior to the date of subsidy change

Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website - https://pharmac.govt.nz/medicine-funding-and-supply/make-an-application/pharmconnect-make-a-medicine-funding-application/process-for-notification-of-product-changes/

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New
Zealand (http://www.pgnz.org.nz/about-us-1/Pharmacode) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (http://www.nzulm.org.nz/sponsors). Pharmacodes and CTPP codes must be provided to Pharmac by the $5^{\text {th }}$ of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode.

## 2022/23 Tender - Principal Supply Status applies until 30 June 2026

Community Pharmaceutical tenders - Section B of the Pharmaceutical Schedule
The decisions were as follows:

1. Tenders awarded to pharmaceuticals where at least one other brand is listed.

| Chemical name | Presentation; <br> Pack size and type | Current pack price | New pack price | Principal Supply brand (Supplier) | Listing date | Principal Supply date | Brand (Supplier) affected by delisting |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Ciprofloxacin | Tab 250 mg ; 28 tablet blister pack | \$2.42 <br> (Cipflox, 28 <br> tab pack) | \$1.95 | Ipca-Ciprofloxacin (Miro) | 1 June 2024 | 1 November 2024 | Cipflox (Viatris) <br> Ciprofloxacin-Torrent (Miro) |
|  |  | \$3.85 <br> (Torrent, 10 <br> tab pack) |  |  |  |  |  |
| Ciprofloxacin | Tab 500 mg ; 28 tablet blister pack | $\$ 4.25$ <br> (10 tab pack) | \$3.10 | Ipca-Ciprofloxacin (Miro) | 1 June 2024 | 1 November 2024 | Ciprofloxacin-Torrent (Miro) |
| Ciprofloxacin | Tab 750 mg ; 28 tablet blister pack | \$5.95 | \$4.80 | Ipca-Ciprofloxacin (Miro) | 1 July 2024 | 1 December 2024 | Cipflox (Viatris) |

Hospital Pharmaceutical tenders - Section H of the Pharmaceutical Schedule.
2. Tenders awarded to pharmaceuticals where at least one other brand is listed.

| Chemical name | Presentation; <br> Pack size and type | Current pack <br> price | New pack <br> price | Principal Supply brand <br> (Supplier) | DV limit | Listing date | Principal Supply <br> date | Brand (Supplier) <br> affected by delisting |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Ciprofloxacin | Tab 250 mg; 28 tablet <br> blister pack | $\$ 2.42$ | $\$ 1.95$ | Ipca-Ciprofloxacin (Miro) | $5 \%$ | 1 June 2024 | 1 November 2024 | Cipflox (Viatris) |


| Chemical name | Presentation; <br> Pack size and type | Current pack <br> price | New pack <br> price | Principal Supply brand <br> (Supplier) | DV limit | Listing date | Principal Supply <br> date | Brand (Supplier) <br> affected by delisting |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Ciprofloxacin | Tab 500 mg ; 28 tablet <br> blister pack | $\$ 4.25$ <br> $(10$ tab pack) | $\$ 3.10$ | Ipca-Ciprofloxacin (Miro) | $5 \%$ | 1 June 2024 | 1 November 2024 | Ciprofloxacin- <br> Torrent (Miro) |
| Ciprofloxacin | Tab $750 \mathrm{mg} ; 28$ tablet <br> blister pack | $\$ 5.95$ | $\$ 4.80$ | Ipca-Ciprofloxacin (Miro) | $5 \%$ | 1 July 2024 | 1 December 2024 | Cipflox (Miro) |

For products included in the 2021/22, 2022/23 and 2023/24 Invitation to Tender where no announcement has yet been made, a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact Pharmac on 0800660050.

